JP2022529312A5 - - Google Patents

Info

Publication number
JP2022529312A5
JP2022529312A5 JP2021556883A JP2021556883A JP2022529312A5 JP 2022529312 A5 JP2022529312 A5 JP 2022529312A5 JP 2021556883 A JP2021556883 A JP 2021556883A JP 2021556883 A JP2021556883 A JP 2021556883A JP 2022529312 A5 JP2022529312 A5 JP 2022529312A5
Authority
JP
Japan
Prior art keywords
approximately
dose
pharmaceutical composition
composition according
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000141 external-priority patent/WO2020194046A1/en
Publication of JP2022529312A publication Critical patent/JP2022529312A/ja
Publication of JP2022529312A5 publication Critical patent/JP2022529312A5/ja
Pending legal-status Critical Current

Links

JP2021556883A 2019-03-25 2020-03-25 低用量の三重複合製剤 Pending JP2022529312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823575P 2019-03-25 2019-03-25
US62/823,575 2019-03-25
PCT/IB2020/000141 WO2020194046A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (2)

Publication Number Publication Date
JP2022529312A JP2022529312A (ja) 2022-06-21
JP2022529312A5 true JP2022529312A5 (enExample) 2023-04-05

Family

ID=72611638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556883A Pending JP2022529312A (ja) 2019-03-25 2020-03-25 低用量の三重複合製剤

Country Status (11)

Country Link
US (1) US20220184070A1 (enExample)
EP (1) EP3946343A4 (enExample)
JP (1) JP2022529312A (enExample)
KR (1) KR20220004026A (enExample)
CN (1) CN113905738A (enExample)
AU (1) AU2020245801A1 (enExample)
BR (1) BR112021018973A2 (enExample)
CA (1) CA3134799A1 (enExample)
MX (1) MX2021011745A (enExample)
TW (1) TW202102208A (enExample)
WO (1) WO2020194046A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019112190A1 (de) 2019-05-09 2020-11-12 Mack Rides Gmbh & Co. Kg Sperrvorrichtung eines Sicherheitsbügels, Fahrgastaufnahme sowie Vergnügungsfahrgeschäft mit einer solchen Sperrvorrichtung
MX2022015333A (es) * 2020-09-02 2023-01-11 Laboratorios Silanes S A De C V Medicamento de combinacion para el control y manejo de la diabetes mellitus tipo 2.
CN113559088A (zh) * 2021-01-21 2021-10-29 江苏宇锐医药科技有限公司 一种含二甲双胍和西格列汀的复方降糖药物制剂
PE20251270A1 (es) * 2022-08-24 2025-05-14 Dong A St Co Ltd Formulacion oral compuesta que comprende evogliptina y metformina, y metodos de preparacion de la misma
WO2025090920A1 (en) * 2023-10-25 2025-05-01 Piton Therapeutics, Inc. Compositions and methods for treating dysfunction of glucose metabolism and/or regulation
CN117599008A (zh) * 2023-11-14 2024-02-27 华中药业股份有限公司 一种西格列汀二甲双胍缓释片及其制作方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
JP5685550B2 (ja) * 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
AU2010212823B2 (en) * 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US20160151382A1 (en) * 2013-10-08 2016-06-02 Kevin Ray Pickering Cooperative Medication Combination Systems
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
KR20180002460A (ko) * 2016-06-29 2018-01-08 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법

Similar Documents

Publication Publication Date Title
JP2022529312A5 (enExample)
JP5077786B2 (ja) 併用医薬
JP2022529208A5 (enExample)
AU2007293885A1 (en) Combination treatment for diabetes mellitus
EP2803360A1 (en) Treatment of pulmonary hypertension with topiramate in combination with a type v phosphodiesterase inhibitor
JP7266327B2 (ja) 高血糖症を処置する方法
US20240366579A1 (en) Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
TW202545526A (zh) 低劑量三重組合調配物
Davis Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus
MX2012011517A (es) El uso de diacereina como una terapia adyuvante para diabetes.
US20190183959A1 (en) Compositions, kits and methods for treating type ii diabetes mellitus
WO2019162800A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
RU2021130019A (ru) Состав низкодозовой тройной комбинации
WO2022089133A1 (zh) 一种降低血糖的组合、应用和方法
HK40097553A (zh) 包括gpr40促进剂以及sglt-2抑制物的医药组成物
CN115192625A (zh) 一种口服组合物
RU2021130142A (ru) Низкодозовый тройной комбинированный состав
Arnouts et al. NDT Perspectives Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
HK1137345A (en) Combination treatment for diabetes mellitus